Update on Clinical Trials in Systemic Lupus Erythematosus

Sonali Narain; Richard Furie


Curr Opin Rheumatol. 2016;28(5):477-487. 

In This Article

Interferonα Kinoid

Neovacs introduced a novel approach to anti-IFN treatment with a recombinant human IFNα conjugated to a strongly immunogenic carrier protein, keyhole limpet hemocyanin. The drug induces transient anti-IFNα antibody titers that neutralize IFNα and disrupts humoral but not cellular tolerance to IFNα.[78,79] A small phase I/II dose-escalation study[80] in 28 women with SLE reported no difference in disease activity between groups.